Prognia
Drug Database
🇪🇺EU · EMAWithdrawn

Comfortis(spinosad)

Marketing Authorisation Holder: Elanco GmbH

EMA Authorisation: 11/02/2011

INN: spinosad

Indication

Treatment and prevention of flea infestations (Ctenocephalides felis). The preventive effect against re-infestations is a result of the adulticidal activity and the reduction in egg production and persists for up to 4 weeks after a single administration of the product. The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Comfortis — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.